Monographie - Paclitaxel

Utolsó frissítés :
19/11/2024

Paclitaxel

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Aclipak	Malaysia
Acoexcel	Mexikó
Actaxel	Svédország
Acupaxil	Peru
Anzatax	Egyesült Arab Emírségek, Szaúd-Arábiában, Törökország
Aritaxel	Németország
Cantaxel	India
Clitaxel	Argentína
Dalys	Argentína
Difren	Argentína
Ebetaxel	Ausztria, Szaúd-Arábiában
Genexol	Magyarország
Onxol	Amerikai Egyesült Államok
Paclinova	Argentína
Paclired	Brazília
Paclitaxin	Hollandia
Parexel	Ecuador
Paxene	Dánia, Finnország, Görögország, Spanyolország
Poltaxel	Lengyelország
Ribotax	Németország
Taxol	Amerikai Egyesült Államok, Ausztrália, Ausztria, Belgium, Colombia, Dánia, Egyesült Arab Emírségek, Egyiptom, Finnország, Franciaország, Görögország, Horvátország, Írország, Japán, Lengyelország, Luxemburg, Magyarország, Malaysia, Marokkó, Nagy-Britannia, Németország, Olaszország, Peru, Portugália, Spanyolország, Svájc, Svédország, Törökország, új-Zéland, Venezuela
Taxomedac	Németország
Vitax	Törökország

Irodalom : Paclitaxel

	Type	publikáció
38	Napló	Allwood MC, Martin HJ. The extraction of diethylhexylphtalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection. Int J Pharm 1996 ; 127: 65-71.
47	Napló	Burm JP, Jhee SS, Chin A, Moon YSK. Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration. Am J Hosp Pharm 1994 ; 51: 1201-1204.
57	Napló	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
85	Napló	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
140	Napló	Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993 ; 50: 1405-1409.
151	Napló	Burm JP, Choi JS, Jhee SS, Chin A, Ulrich RW, Gill MA. Stability of paclitaxel and fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 2704-2706.
157	Napló	Xu QA, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32°C. Am J Hosp Pharm 1994 ; 51: 3058-3060.
158	Napló	Trissel LA, Xu QA, Kwan J, Martinez JF. Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets. Am J Hosp Pharm 1994 ; 51: 2804-2810.
173	Napló	Williams DA, Naik A. Precipitation of paclitaxel from continuous infusion fluids. J Infus Chemother 1994 ; 4: 140-142.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
248	Napló	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
250	Napló	Mazzo DJ, Nguyen-Huu JJ, Pagniez S, Denis P. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm 1997 ; 54: 566-569.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
412	Napló	Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991 ; 48: 1520-1524.
669	Napló	Chin A, Ramakrishnan RR, Yoshimura NN, Jeong EWS, Nii LJ, DiMeglio LS. Paclitaxel stability and compatibility in polyolefin containers. Ann Pharmacotherapy 1994 ; 28: 35-36.
872	Napló	Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacotherapy 1997 ; 31: 1465-1470.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Napló	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1286	Napló	Trissel LA, Xu QA, Gilbert DL. Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions. Ann Pharmacotherapy 1998 ; 32: 1013-1016.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Napló	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laboratórium	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1522	Laboratórium	Macoflex N® Maco Pharma 2001
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Napló	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1741	Napló	Pfeifer RW, Hale KN, Cronquist SE, Daniels M. Precipitation of paclitaxel during infusion by pump. Am J Hosp Pharm 1993 ; 50: 2518-2521.
1865	Napló	Sautou-Miranda V, Brigas F, Vanheerswinghels S, Chopineau J. Compatibility of paclitaxel in 5% glucose solution with ECOFLAC® low-density polyethylene containers - Stability under different storage conditions. Int J Pharm 1999 ; 178: 77-82.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1940	Napló	Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1953	Napló	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1956	Laboratórium	Paclitaxel - Summary of Product Characteristics Hospira UK Limited 2015
1961	Napló	Kim SC, Yoon HJ, Lee JW, Yu J, Park ES, Chi SC. Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. Int J Pharm 2005 ; 293: 303-310.
1982	Napló	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2014	Napló	Pourroy B, Botta C, Solas C, Lacarelle B, Braguer D. Seventy-two-hour stability of Taxol® in 5% dextrose or 0.9% sodium chloride in Viaflo®, Freeflex®, Ecoflac® and Macoflex N® non PVC bags. J Clin Pharm Ther 2005 ; 30: 455-458.
2172	Napló	Donyai P, Sewell GJ. Physical and chemical stability of paclitaxel infusions in different container types. J Oncol Pharm Practice 2006 ; 12, 4: 211-222.
2174	Napló	Kattige A. Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions. EJHP Science 2006 ; 12, 6: 129-134.
2262	Napló	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2344	Laboratórium	Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution. Ebewe Pharma 2009
3093	Napló	Tian J, Stella VJ. Degradation of paclitaxel and related compounds in aqueous solutions III: Degradation under acidic pH conditions and overall kinetics J Pharm Sci 2010 ; 99, 3 : 1288-1298.
3277	Napló	Yang Z, Cameron S, Paul H. Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration. Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3578	Laboratórium	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011

Mentions Légales